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Abstract
Background: Patients chronically infected with hepatitis C virus (HCV) require significantly different durations of therapy
and achieve substantially different sustained virologic response rates to interferon-based therapies, depending on the HCV
genotype with which they are infected. There currently exists no systematic framework that explains these genotype-
specific response rates. Since humans are the only known natural hosts for HCV–a virus that is at least hundreds of years
old–one possibility is that over the time frame of this relationship, HCV accumulated adaptive mutations that confer
increasing resistance to the human immune system. Given that interferon therapy functions by triggering an immune
response, we hypothesized that clinical response rates are a reflection of viral evolutionary adaptations to the immune
system.
Methods and Findings: We have performed the first phylogenetic analysis to include all available full-length HCV genomic
sequences (n=345). This resulted in a new cladogram of HCV. This tree establishes for the first time the relative evolutionary
ages of the major HCV genotypes. The outcome data from prospective clinical trials that studied interferon and ribavirin
therapy was then mapped onto this new tree. This mapping revealed a correlation between genotype-specific responses to
therapy and respective genotype age. This correlation allows us to predict that genotypes 5 and 6, for which there currently
are no published prospective trials, will likely have intermediate response rates, similar to genotype 3. Ancestral protein
sequence reconstruction was also performed, which identified the HCV proteins E2 and NS5A as potential determinants of
genotype-specific clinical outcome. Biochemical studies have independently identified these same two proteins as having
genotype-specific abilities to inhibit the innate immune factor double-stranded RNA-dependent protein kinase (PKR).
Conclusion: An evolutionary analysis of all available HCV genomes supports the hypothesis that immune selection was a
significant driving force in the divergence of the major HCV genotypes and that viral factors that acquired the ability to
inhibit the immune response may play a role in determining genotype-specific response rates to interferon therapy.
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Introduction
Nearly170millionpeopleworldwidearechronicallyinfectedwith
hepatitis C virus (HCV) [1]. In the US, HCV is the leading cause of
hepatocellular carcinoma and the leading indication for liver
transplantation [2]. The standard of care for the treatment of
chronic hepatitis C is combination therapy with pegylated interferon
and ribavirin. Pegylated interferon (PEG-IFN) is a synthetic variant
of interferon-a, a naturally occurring cytokine whose endogenous
role is to activate the innate immune response. Injected PEG-IFN is
hypothesized to function by mimicking this natural cytokine.
Ribavirin (RBV) is a nucleoside analog. It is thought to act through
a combination of modalities (as reviewed in [3,4]).
Large clinical trials of PEG-IFN/RBV therapy have revealed
significantly different response rates forthe various HCVgenotypes.
There are six major HCV genotypes, numbered 1 to 6. Genotype 2
is the most responsive, with a sustained virologic response (SVR)
rate of greater than 80%. Studies also suggest that it is reasonable to
treat some patients infected with this genotype for only 12–16 weeks
[5,6,7]. Conversely, the most prevalent genotype worldwide,
genotype 1, is the least responsive. The SVR rate for patients
infected with genotype 1 is less than 50%. Current guidelines
recommend 48 weeks of therapy for this genotype; shorter courses
of therapy have been demonstrated to be sub-optimal [8].
There currently exists no systematic explanation for these
genotype-specific differences in clinical outcome [4,9,10]. It is
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of a confluence of host and viral factors. What specific host factors,
human demographics/geographic patterns, and/or viral factors
determine interferon response rates remains a challenging area of
inquiry. Furthermore, whether factors that govern outcome for
one genotype play a similar role in other genotypes remains to be
more fully explored.
Numerous laboratory studies suggest that certain viral factors
are able to inhibit aspects of the innate immune response (as
reviewed in [11,12,13]). These cell culture studies, however,
highlight the gap that currently exists between laboratory models
and the human host. For example, the HCV replicon system
allows for the study of HCV RNA replication in cell culture. Using
this system, it was observed that genotype 2 replicons were more
resistant to interferon than genotype 1 replicons, the opposite of
what is observed clinically [14]. Thus, this observation may be a
culture system artifact [15] that highlights the challenge of
ascertaining the clinical relevance of findings first discovered in
laboratory models.
HumansaretheonlyknownnaturalhostsforHCV,avirusthatis
estimated to be hundreds and possibly thousands of years old
[16,17,18]. This lengthy relationship may have allowed HCV to
accumulate adaptive mutations that confer increasing resistance to
the human immune system. Interferon therapy functions by
activating the innate immune response, which is comprised of
direct intracellular defenses such as the PKR, Mx and RNaseL
proteins, and innate immune cells, including NK, dendritic,
monocyte, macrophage, and NKT cells. Once activated, the innate
immune system also plays a critical role in the proper stimulation
and coordination of the adaptive immune response [13,19].
We therefore hypothesize that genotype-specific clinical re-
sponse rates to interferon-based therapies are a reflection of HCV
evolutionary adaptations to the immune system. We do not
hypothesize that modern interferon therapy itself selected for the
various HCV genotypes. Instead, we are hypothesizing that the
immune system that is activated by interferon therapy has co-
evolved with HCV.
One evolutionary pattern that would strongly indicate that a
selective pressure was favoring adaptations to the immune system
would be a strict correlation of increasing non-response to
treatment with the relative ages of the genotypes—such that, as
each new genotype emerged it would have a more resistant
phenotype than its ancestor.
HCV was first divided into genotypes by the seminal work of
Simmonds and others in 1993 [20,21], based on an analysis of one
segment of the HCV genome from 76 different patients
(Figure 1A). Evolutionary analysis limited to only portions of a
genome, however, can be misleading [18,21,22]. For instance, by
analyzing 27 full-length HCV genomes Salemi and colleagues [23]
(Figure 1B) found a different phylogenetic pattern for the
relationships amongst the six HCV genotypes. Also of note is that
neither analysis determined the relative evolutionary ages of the
various genotypes.
Determining the relative ages of the major HCV genotypes is
critical to testing our hypothesis that a correlation exists between
genotype age and clinical resistance. Relative ages can be
determined through the use of an outgroup, which roots the
phylogeny and establishes the direction of time. In the analysis
presented here, we used GB Virus B (GBV-B) as an outgroup. This
allowed us to root our HCV phylogeny and establish for the first
Figure 1. Unrooted HCV Cladograms From Previous Studies. Panel A shows the first cladogram to divide HCV into six genotypes, based on a
neighbor-joining analysis of the NS5 region of HCV that included 76 sequences (Simmonds et al. 1993). Panel B shows a more recent HCV consensus
tree with a different genotype branching pattern compared to Panel A, based on an analysis of 27 full-length HCV genomic sequences (Salemi et al.
2002). The table below each panel indicates the genotype distribution of the sequences analyzed in these studies.
doi:10.1371/journal.pone.0006579.g001
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chosen as the outgroup for two reasons: first, GBV-B, a virus that
causes hepatitis in New World monkeys, is the closest viral relative
of HCV and the only other member of the hepacivirus genus. Second,
biochemical evidence suggests that proteins in GBV-B share highly-
specific functionality with their homologs in HCV [24].
The evolutionary analyses of HCV that have been performed to
date have also been based on a limited number of genomic
sequences. A prime reason for this is that reliable methods of tree
construction, such as maximum likelihood (ML) and maximum
parsimony (MP), require considerable amounts of computational
power. Thus, often only a subset of available sequences is actually
analyzed. For this reason, Salemi et al. limited their analysis to 27
genomes.
In this work, we perform a comprehensive analysis of all the
.300 genomes found in the European HCV database. This order
of magnitude increase in the number of genomes analyzed was
made possible by the NSF-funded Cyberinfrastructure for
Phylogenetic Research (CIPRES) Project, which allows for web-
based access to the San Diego Super Computer facility and newly
developed evolutionary algorithms that dramatically reduce
computational time.
We thus sought to construct the first evolutionary tree of HCV
that incorporated all known genomic sequences and would allow
for the relative ages of all HCV genotypes to be determined. We
then used this tree to test our hypothesis that clinical resistance to
interferon correlates with HCV genotype age. Finally, we used
ancestral sequence reconstruction to identify HCV loci that
potentially play a role in determining genotype-specific clinical
outcomes.
Methods
Sequence Selection and Alignment
All 348 full-length HCV genomic sequences publicly available
as of October 2007, were downloaded from the European HCV
database [25]. Reflecting its wider prevalence, 236 of these
sequences were genotype 1. Forty-five sequences were genotype 2,
seven were genotype 3, ten were genotype 4, two were genotype 5,
and forty-five were genotype 6. Three sequences were putative
recombinants and were discarded.
Two separate methods were used to align the coding regions of
these sequences, in order to address potential alignment strategy
biases. The first method utilized ClustalX [26] followed by
inspection, which ensured that the alignment respected known
viral protein properties. The second alignment method, MAFFT
[27], was fully automated. Over 90% of the HCV genome encodes
a single polyprotein. To ensure in-frame alignment, amino acid
sequence alignments were first generated and then used to guide
the nucleic acid sequence alignments. For both alignment
programs, gap opening and extension parameters were set to
their defaults.
GBV-B was selected as the outgroup because it is the closest
known viral relative of HCV that is not thought to fall within the
HCV clade [24,28,29]. Broadening the outgroup to include GB
virus A and GB virus C was not possible because the alignment of
these viruses to HCV was poor. Thus, these viral sequences were
not used in our analyses.
Phylogenetic Analyses
Our two amino acid alignments and the two nucleotide (NT)
alignments, each alignment having been generated by the two
alignment methods described above, were then analyzed using
ML, MP, and neighbor-joining (NJ) techniques (Figure 2).
Additionally, a combined alignment was created by concatenating
our amino acid and nucleotide datasets into a single matrix. This
combined alignment was then analyzed using the MP method.
Combining amino acid sequences with nucleotide sequences has
been proposed as a method for extracting as much information
from sequences as possible and acting to weigh protein coding
amino acid data without a priori transformation costs [30].
PAUP [31] was used to perform the NJ analyses. The minimum
evolution criterion was used and branch lengths were allowed to
be negative except when calculating tree scores. In this situation,
branch lengths were set to zero. Ties were broken randomly. The
best NJ tree (amino acid dataset) score was 29.09196; the best NJ
tree (nucleotide dataset) score was 212.83397.
For MP analyses, the program PAUPRat [32] in conjunction
with PAUP [31] was used to perform an aggressive search using
the Ratchet method [33]. 200 ratchet iterations were performed
for each dataset with random addition (RA) followed by tree
branch reconnection (TBR) swapping, randomly upweighting
Figure 2. Flow Chart of the Evolutionary Analyses Performed in This Study. ML: maximum likelihood; MP: maximum parsimony; NJ:
neighbor joining; MAFFT: multiple sequence alignment based on fast Fourier transform.
doi:10.1371/journal.pone.0006579.g002
HCV Evolution and IFN Therapy
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e657915% of characters at each iteration and saving only one tree at
each iteration. The resulting trees were then used as starting trees
for TBR searching using the Multrees option in PAUP. Gaps were
treated as a state and all characters and state transformations were
weighted equally. Bootstrap values were calculated using 100
bootstrap iterations, using 10 replicates of RA followed by TBR in
each iteration [29]. The data set for each iteration was generated
by re-sampling (with replacement) the characters in the alignment.
Bremer supports [29] were calculated using the program
Autodecay [34] in conjunction with PAUP, using 10 TBR
replicates for each node in the MP phylogeny. See Table 1 for
MP tree scores and statistics.
ML NT analyses were performed using GARLI [35], via the
CIPRES portal [36]. Prior ML analyses used a GTR+Gamma site
model [37]. We used the program HYPHY [38] to perform both
exhaustive and hierarchical model testing based on the likelihood
ratio, and determined the optimal model to be GTR+gamma+in-
variant. Nevertheless, use of invariant sites did not affect the tree
structure determined (data not shown). The shape of the gamma
function was inferred from the data set. More than 35 separate
ML analyses were performed, in order to address stochastic
concerns and better ensure that the resultant tree had the optimal
maximum likelihood. The optimal NT ML tree -lnL score was
594309. RAxML[39] was used to assess node support with 100
rapid bootstrap replicates. Bootstrap values were drawn on the
best-scoring GARLI ML. RAxML was also used for amino acid
analyses, using a WAG+Gamma+F model. The optimal AA ML
tree -lnL score was 198250. At the time of our analyses, the
CIPRES server used RA with no Multrees and no swapping for
heuristic tree searching. Out of concern that this less aggressive
search strategy might limit our ML analyses, we also used as
starting trees the outputs from our more aggressive MP search
strategy. Resultant trees were unchanged.
Evaluating Taxon Sampling
All available whole HCV genomes were initially analyzed,
based on the assumption that adding taxa increases phylogenetic
accuracy [40]. As a consequence, genotype 1 sequences repre-
sented 236/345 of the analyzed genomes. We utilized two
approaches to address the potential bias introduced by this uneven
taxonomic sampling. First, we performed our analyses using three
different optimality criteria, since uneven taxon sampling might be
expected to cause the various optimality criteria to produce
different phylogenetic trees [41,42]. Second, we utilized a taxon
jackknifing technique. In our jackknife analyses, genotype 5
sequences were excluded, as only two existed. Each jackknifed
dataset was constructed by randomly selecting seven taxa per
genotype, without replacement, from the initial alignments. The
number seven was selected as this represented the number of taxa
in genotype 3, the second least represented genotype. Random
selection was performed 10 times, for each of the amino acid,
nucleotide and concatenated alignments, resulting in 30 datasets,
each of which consisted of 35 taxa plus the outgroup GBV-B. All
of the above described analyses were then repeated on these
datasets.
Clinical Trial Data Compilation
A PubMed search for English language, prospective trials that
studied the effect of PEG-IFN/RBV combination therapy for the
treatment of chronic hepatitis C was used to identify relevant trials.
Published reviews were also consulted to ensure comprehensive-
ness [8,43]. Studies published (including early e-publication) up to
December 2007 were included. The fact that sustained virologic
response rates vary according to genotype has already been well-
established [5,8,43,44,45,46]. For illustrative purposes, were
therefore compiled here only the major, large prospective trials.
Specifically, early trials with less than 100 patients in total or arms
with less than 25 patients were excluded, except in the case of
genotype 4 for which there primarily exist a limited number of
smaller trials. For genotype 4, trials with less than 25 patients were
excluded. Published non-inferiority trials comparing different
PEG-IFN formulations were also excluded, as they assessed only
end-of-treatment virologic response. The genotype-specific clinical
response rates shown are based on intention-to-treat analyses, and
represent averages weighted according to the number of patients
in each indicated study (Table 2). Notably, clinically relevant
differences in outcome among HCV sub-genotypes (subtypes) [8]
have not been observed. Our approach was therefore limited to
genotype-level outcome data.
Testing Correlation
Standard tests of correlation are not appropriate for items that
are related by descent in an evolutionary hierarchy [47,48]. We
therefore used Shimodaira’s approximately unbiased (AU) tree-
based statistical test [49,50] to evaluate the critical nodes within
our tree topology and test the statistical significance of our
observed correlation between relative genotype age and SVR.
Specifically, we constrained the clade including genotypes 1 and 4
not to exist in our optimal tree (Tno1,4). We then constrained the
clade including genotypes 1, 3, 4, and 5 to not exist in our optimal
tree (Tno1,4,3,5). Each of these alternate trees, which disrupt the
evolutionary branching pattern of the major genotypes, was then
tested against the optimal ML tree using Shimodaira’s AU test
with the RELL bootstrap approximation (1000 replicates), to
determine if they were statistically inferior. These analyses were
carried out using the program CONSEL [51].
Identification of Viral Resistance Loci
Fitch optimization [52] was used to reconstruct the ancestral
protein sequence at each of the three nodes that lie on the main
trunk of our tree [53,54]. These ancestral sequences were then
screened, in two steps, to identify the positions that correlate with
Table 1. Parsimony Tree Statistics.
Optimal
Score
(Clustal)
No. of
Trees Found
(Clustal)
Consistency
Index
Retention
Index
Rescaled
Consistency
Index
Consensus
Fork Index
Rohlf
Consensus
Index
Total No. of
Characters
(Parsimony Informative)
AA+NT 175615 228 0.162 0.76 0.123 0.901 0.806 12881 (8107)
NT 140497 32 0.125 0.752 0.094 0.977 0.959 9669 (6227)
AA 3334 31104 0.293 0.799 0.234 0.936 0.94 3212 (1880)
doi:10.1371/journal.pone.0006579.t001
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from sequence mutation, these ancestral sequences were screened
to identify residues that had undergone mutation as HCV evolved
along the main trunk of the tree. These positions were then
screened to identify positions that, having mutated, conserved the
particular mutation in all future progeny. This second screening
step is based on the assumption that functionally advantageous
mutations are likely to be conserved.
Results
The results of each individual phylogenetic analysis are shown
in Figure 3. Regardless of whether amino acid or nucleotide
sequence data was analyzed, or which of the two alignment
methods were utilized, striking concordance was found to exist
among the three phylogenetic inference methods. Individual
optimal trees from each analysis were also supported by bootstrap
values and/or Bremer decay indices, and differed only in the
placement of genotypes 5 and 6. In all but one case (parsimony
nucleotide analysis) the relative branching order of those
genotypes with prospective clinical outcome data (i.e. genotypes
1, 2, 3, and 4) was identical.
The end result of our phylogenetic analyses is summarized in
figure 4, left panel. It reveals that HCV genotype 2 branched first,
genotypes1 and4 branchedlast,and genotypes3,5,and 6 branched
sometime after genotype 2 but before genotype 4. Using population
genetic methods to analyze limited portions of the genome from a
sampling of genotypes (1, 4, and 6), Pybus and colleagues [16,18]
estimated origin times for genotypes 1, 4 and 6 that are notably
concordant with the more complete branching order we have
determined. Other studies [17,18,55] have inferred the absolute age
of certain HCV sub-genotypes/subtypes (e.g. 1a, 1b and 3a) and
found them to be relatively recent; these finding do not contradict
the relative ages we have inferred for the major genotypes.
To gauge the effect of taxon sampling on our phylogenetic
analysis, we performed the taxon jackknife technique described
above, in which we randomly selected an equal number of taxa
from each genotype for repeated analyses. All jackknife replicates
using the amino acid data, for all optimality criteria (ML, NJ, and
MP), gave exactly the same genotype branching order seen in
Figure 4. For nucleotide data, jackknife replicates analyzed using
NJ and MP methods also resulted in the same branching order.
Likewise, the combined amino acid and nucleotide datasets
analyzed using MP criteria were 100% concordant with the
overall consensus. The ML analyses of the jackknifed nucleotide
data sets resulted in inconsistent branching patterns. Only one ML
NT jackknifed data set reslted in a tree with the same branching
pattern as seen in our overall consensus. The remaining nine
differed amongst each other in the location of the root and/or
overall topology, with most rooting within or near genotype 6.
A compilation of the outcome data from 19 prospective trials of
combination therapy with PEG-IFN/RBV to treat chronic
hepatitis C is shown in Table 2. As has been previously observed
[5,8,43,44,45,46], genotype-specific response rates are hierarchi-
cal. From highest to lowest, the pattern of SVR rates is: genotype
2.genotype 3.genotype 4.genotype 1. There currently exist no
prospective trials of PEG-IFN/RBV therapy for genotypes 5 and
Table 2. Prospective HCV Trials of Therapy with Pegylated Interferon and Ribavirin.
Genotype Avg. SVR Therapy Duration Patients Study Specific SVR
a
1 46% 48 wks 917 Hadziyannis et al. 2004 [44] 52% (141/271)
Fried et al. 2002 [102] 46% (137/298)
Manns et al. 2001 [45] 42% (145/348)
2 82% 12–24 wks 788 Dalgard et al. 2008
b [103] 97% (30/31)
Shiffman et al. 2007
b [6] 75% (268/356)
Yu et al. 2007 [7] 95% (142/150)
Mangia et al. 2005 [5] 80% (171/213)
Von Wagner et al. 2005 [104] 92% (35/38)
3 72% 12–24 wks 657 Dalgard et al. 2008
b [103] 92% (106/115)
Shiffman et al. 2007
b [6] 66% (244/369)
Mangia et al. 2005 [5] 66% (46/70)
Von Wagner et al. 2005 [104] 73% (75/103)
4 60% 24–48 wks 676 Kamal et al. 2007 [46] 63% (239/378)
Derbala et al. 2005 [105] 29% (10/35)
Kamal et al. 2005 [106] 70% (48/69)
El-Zayadi et al. 2005 [107] 55% (22/40)
Alfaleh et al. 2004 [108] 43%(12/28)
Hasan et al. 2004 [109] 68% (45/66)
Shobokshi et al. 2003
c 50% (30/60)
5 No prospective trials of pegylated interferon and ribavirin
6 No prospective trials of pegylated interferon and ribavirin
aSustained Virologic Response: Number of patients with no detectable virus 6 months after completion of therapy divided by the total number of patients treated,
based on intention-to-treat analyses.
bData from the 24 week arm of the study.
c2003 AASLD Abstract # 996.
doi:10.1371/journal.pone.0006579.t002
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genotypes (i.e. 1a versus 1b) have clinically relevant differences in
outcome [8], though evidence exists that sequence variations
within subtypes may affect clinical outcome [56,57]. Therefore,
the present study was restricted to a genotype-level analysis of
clinical response and sequence evolution.
When genotype-specific clinical response rates were mapped
onto our phylogenetic tree, a correlation between genotype age
and clinical resistance was revealed (Figure 4). As hypothesized,
early branching genotypes were noted to have the best clinical
outcomes and require the least duration of therapy, while
genotypes that branched later (i.e. more recently) have higher
rates of clinical resistance and need to be treated for much longer.
Therefore, each newly emerged genotype has greater resistance
than its ancestor, indicating the likely presence of a selective
pressure favoring resistance. To test the statistical significance of
Figure 3. Rooted Neighbor-Joining (NJ), Maximum Parsimony (MP), and Maximum Likelihood (ML) cladograms depicting the
evolution of the major hepatitis C virus genotypes. A nexus file of complete tree data is available online (Dataset S1). Numbers represent
bootstrap support and Bremer decay indices. AA: amino acid sequences; NT: nucleotide sequences.
doi:10.1371/journal.pone.0006579.g003
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applied Shimodaira’s AU test (see Methods). Briefly, we searched
for the best possible trees that disrupted the observed branching
pattern and compared their likelihoods to the likelihood of our
optimal tree. In every case, trees that contradicted our tree
topology and disrupted the observed correlation with interferon
susceptibility were significantly suboptimal (P,0.01). Thus, by this
rigorous standard, the observed correlation is statistically signifi-
cant. A far more conservative estimate of the significance of this
correlation was calculated using the equation, N=(2n23)!/
2n22(n22)!, where n is the number of taxa (in this case,
genotypes are the taxa), and N equals the number of ways in which
taxa can be ordered on a branching tree. Thus there were a total
of N=15 possible ways in which the 4 genotypes with known
clinical outcomes could be ordered on our tree, making the
likelihood of a tree pattern that matched SVR outcomes, purely by
chance, equal to 1 out of 15.
This correlation between clinical resistance and branching order
allows for the following prediction: prospective clinical trials of
genotypes 5 and 6 using PEG-IFN/RBV, for which prospective
data is currently lacking, will likely show intermediate SVR rates,
similar to genotype 3. Antaki and colleagues have published a
retrospective study of genotype 5 infected patients treated with
PEG-IFN/RBV. By this retrospective analysis, genotype 5 infected
patients have an SVR rate of 67% [58], exactly as our tree
predicts.
Ancestral sequence reconstruction, as described in Methods,
was then used to identify viral elements potentially responsible for
this clinical resistance trend. Our analysis resulted in 55 hot spots:
positions that mutated as HCV became increasingly resistant. The
locations of these hotspots are shown in Figure 5. N1 denotes
positions associated, by reconstruction analysis, with genotype 1
being more resistant than any other genotype; N2 denotes
positions associated with genotypes 1 and 4 being more resistant
than genotypes 2, 3, 5, and 6; N3 denotes positions associated with
genotypes 1, 3, 4, 5, and 6 being more resistant than genotype 2.
These hotspots were then binned in groups of 50 amino acids,
resulting in the frequency histogram shown at the top of Figure 5.
This histogram identifies the two 50 amino acid regions of the
HCV genome that contain the greatest number of hotspots. These
two regions fall within the PKR binding domains of the E2 and
NS5A proteins of HCV [59,60], suggesting their potential
importance as viral factors that may determine genotype-specific
responses to interferon therapy.
Discussion
In this study, the relative evolutionary age of HCV genotypes
has been shown to correlate with the likelihood of a sustained
virologic response to interferon-based therapies (Figure 4). We
suggest that the observed correlation stems from consistent
selective pressure generated by the host immune system. However,
a number of alternative explanations could account for the
observed correlation between response to interferon-based thera-
pies and relative genotype age. It is possible that the observed
correlation is a product of chance, bias, or analytical limitations.
Alternatively, the branching pattern may be accurate, but the
patterns may not be directly causally related. We discuss each of
these possibilities below, as well as the current experimental
evidence in favor of immune-mediated selection.
With regard to chance, bias, or potential analytical limitations,
our results are dependent on the reliability of evolutionary
reconstruction techniques and limitations of the data set. We
have attempted to address these concerns through the use of three
different techniques (NJ, ML, and MP), two alignment methods,
and rigorous statistical testing. Our approach included performing
bootstrap and Bremer decay index analyses to measure support for
branches. Importantly, we note that neither the small discrepan-
cies that exist between phylogenetic techniques, nor areas of
weaker support, contradict the overall branching pattern of the
tree.
As many available whole HCV genomes as possible were
analyzed based on the assumption that adding taxa increases
Figure 4. Rooted Consensus Cladogram Resulting From An Analysis of 345 Full-Length HCV Genomic Sequences. The evolution of the
major (HCV) genotypes and their correlation to clinical outcome is depicted. Values denote bootstrap support and Bremer decay indices for the
indicated phylogenetic inference method.
doi:10.1371/journal.pone.0006579.g004
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more well-sampled than other genotypes, this assumption may
have introduced a bias due to uneven taxonomic sampling. Such
uneven taxon sampling might be expected to cause the various
optimality criteria used here to produce different phylogenetic
trees [41,42]; however, we have shown that they essentially do not.
One could further argue that all phylogenetic optimality criteria
may have been affected by uneven taxon sampling bias in the
same way, leading each to converge on the wrong answer. To
address this possibility, we utilized a taxon jackknifing technique,
in which an equal number of taxa were randomly selected from
each of the genotypes for analysis. This random selection process
was repeated 10 times for each type of dataset. For all dataset
types, for all inference methods (except the ML analyses of the NT
datasets), and for all jackknife replicates, exactly the same genotype
branching pattern was obtained. Thus, the observed genotype
branching pattern appears robust both to reducing the number of
taxa and to equalizing the number of genotype representatives.
Sparse taxon sampling, as opposed to uneven taxon sampling,
may have resulted in greater uncertainty of branch placement for
less represented genotypes, such as genotype 5, for which only 2
full-length sequences were available. This uncertainty (as reflected
in figure 3), led to the inability to determine a definitive
relationship of genotype 5 to genotypes 3 and 6. We could only
determine that it branched after genotype 2, and before genotypes
1 and 4.
The above tests control for the possibility that the branching
pattern of the tree itself was the result of analytical limitations,
bias, or chance. To gauge the validity of the observation that this
branching order correlates with clinical response to interferon, we
used a battery of comparisons based on Shimodaira’s AU test.
Notably, the AU test showed that alternative tree topologies that
disrupt the observed correlation are statistically highly unlikely.
With regard to whether this correlation is the result of a causal
relationship, we note that our data satisfies a number of criteria
commonly used to address the plausibility of causality in statistical
analyses (i.e. the Hill criteria [61]). First, we show a biological
gradient of responsiveness that correlates with increasing genotype
age, with all four genotypes that have well-defined clinical
outcomes adhering to this pattern (Figure 4). Second, ancestral
sequence reconstruction was used to identify viral proteins
putatively involved in genotype-specific immune resistance. These
same proteins have been independently identified in biochemical
analyses [36,37] to have the ability to inhibit the innate immune
response. Thus, the observed correlation has mechanistic plausi-
bility and is consistent with other evidence. Third, biochemical
experimentation has been able to reproduce some of the biological
gradient we predict. The ability of the E2 and NS5A proteins to
inhibit PKR is genotype-specific and consistent with our
evolutionary tree [59,60]. An analysis of host cleavage of viral
RNA by the RNaseL defense pathway is also consistent with our
observed trend [62,63]. For these reasons, it is reasonable to
hypothesize that a causal relationship explains our observations,
while recognizing that further experimental evidence is needed.
Possible Mechanisms of Immune Selection
Our phylogenetic results are consistent with our hypothesis that
a selective pressure generated by the host immune system has
played a significant role in HCV evolution and the divergence
of genotypes. The specific combination of interferon-induced
Figure 5. HCV Resistance Loci. Positions (‘‘hotspots’’) in the HCV genome that appear to have undergone directed change with respect to
immune resistance. N1: positions associated, using ancestral sequence reconstruction techniques, with genotype (GN) 1 being the most resistant. N2:
positions associated, using ancestral sequence reconstruction techniques, with GNs 1 and 4 being more resistant than GNs 2, 3, 5, and 6. N3: positions
associated, using ancestral sequence reconstruction techniques, with GNs 1, 3, 4, 5, and 6 being more resistant than GN 2. A hotspot histogram
(binned in groups of 50 amino acids) is shown at the top. The 10 proteins encoded by the HCV genome are also illustrated. Two loci were identified
with the highest density of hotspots (black bars); these loci map to the PePHD domain of E2 and the PKR binding domain of NS5A, both of which
have been shown to inhibit the innate immune factor PKR.
doi:10.1371/journal.pone.0006579.g005
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largely a matter of speculation.
For example, given that interferon can cause an up-regulated,
multi-specific, HCV-specific CD4+ T-cell response [64], one
possibility is that genotype-specific differences in clinical outcome
are the result of differences in antigenicity [65]. Patients who
progress to chronic infection compared to those that resolve their
acute infection have increased viral diversity in their envelope gene
E2. Thus, diversity may be a product of the emergence of antibody-
selected escape variants [66]. HCV escape variants selected by
CD8+ T cells, which recognize other regions of the virus, have also
beenobserved [67,68,69,70].It remains to be determined, however,
whether these observed micro-evolutionary processes are the same
macro-processes that produced genotype divergence.
An alternative and non-mutually exclusive possibility is that
HCV genotype-specific differences in clinical outcomes are the
result of the ability to cause immune dysfunction. Patients with up-
regulated interferon stimulated genes (ISG) prior to therapy are
likely to be non-rapid responders [71,72]. One possible interpre-
tation of this data is that HCV causes immune dysfunction. ISGs
are up-regulated but non-functioning or uncoordinated in their
response [12]. Notably, an up-regulated ISG state was found to be
more prevalent in more refractory genotypes, such as genotype 1
and 4, than 2 and 3 [72].
Yet another possibility is that genotype-specific outcomes are
the result of direct inhibition of the intracellular immune pathways
within liver cells. One key interferon intracellular pathway
activates double-stranded RNA-dependent protein kinase (PKR).
PKR shuts down protein production in infected cells, preventing
them from being used as factories for virus production.
Biochemical and cell culture studies have determined that HCV
proteins E2 and NS5A are capable of inhibiting PKR activation
[59,60]. Notably, the motif of E2 that we identified as having key
ancestral sequence changes that correlated with genotype immune
differentiation is the same region identified by biochemical analysis
to be critical for E2 inhibition of PKR–the PKR-eiF2a
phosphorylation homology domain (PePHD). Critically, the ability
of E2 to inhibit PKR was found to be specific to genotype 1 [59],
the genotype most strongly associated with non-response to
therapy [8]. Similarly, our ancestral sequence reconstruction
analysis identified the same NS5A locus determined by biochem-
ical studies to be important for NS5A inhibition of PKR (PKR
binding domain) [60]. Shimotohno and colleagues have observed
that the ability of NS5A to inhibit PKR is genotype specific: NS5A
from genotype 1 is able to inhibit the innate immune factor PKR,
but the NS5A protein from genotype 2 cannot [73]. This
biochemical observation can now be explained by our evolution-
ary analysis.
Another defense mechanism activated by interferon is the
RNaseL pathway. When activated, RNaseL cleaves viral RNA.
Evidence suggests that genotype 1 is the most resistant of all
genotypes to RNaseL, while genotypes 2 and 3 are these least
resistant [62,63]. Such differences in RNaseL susceptibility are
likely mediated by differences in nucleotide composition. This data
is also consistent with our observed correlation between relative
genotype age and clinical responsiveness. Notably, a number of
other viral factors in HCV that help it overcome the immune
response (as reviewed in [12,13]), have been described. The vast
majority of these studies, however, involved only HCV genotype 1.
Extending such studies to other genotypes would shed much light
on the immunobiology of this virus. Such studies may also
eventually reveal that PKR inhibition and RNaseL evasion are
only a subset of the genotype-specific defense mechanisms that
have evolved as a result of immune selection.
Origins of Current HCV Diversity
Our results raise an important secondary question: Why have
the more interferon sensitive genotypes (e.g. genotype 2) not
become equally resistant over time, especially given the high
mutation rate of HCV? At least four, non-mutually exclusive
possibilities might explain a pattern in which certain descendants
have a beneficial phenotype while other relatives do not.
First, the beneficial trait could have evolved in a specific
historical epidemiological context. Given the phylodynamic
pattern of HCV [74], this is quite possible. The opportunity for
early HCV genotypes to acquire certain traits may have already
passed.
Second, the beneficial trait could be relatively difficult to
acquire from a genetic perspective. Although HCV has a high
mutation rate, a high mutation rate does not necessarily imply that
certain traits will be easily acquired (as reviewed in detail by Smith
and Simmonds [75]). For HCV specifically, immune resistance
may be difficult to acquire due to structure-functional restrictions
on the mutagenic space that current HCV strains can explore.
Studies have shown that all of the HCV non-structural proteins
interact with one another [76]. Mutation is thus limited to non-
critical regions or would require multiple, simultaneous compen-
satory mutations that preserve function. Mutation space in HCV is
further constrained by genome ordered RNA structure (GORS)
[77]. Significant RNA structure has been found to underlie the
entire HCV polyprotein, which would further limit the ability of
HCV to mutate without disrupting critical structure-function
relationships. [65,75].
The existence of structure-function limitations on the genetic
diversity of HCV is clear from the fact that mutations in HCV are
not homogeneously distributed [65,69,75,78,79,80]. Mutations are
over-represented in defined hypervariable regions such as the N-
terminal half of E2, which is where antibodies have been found to
bind [66,81]. Conversely, the C-terminal region of E2 that we and
others identify as significant for genotype-specific inhibition of
PKR is quite static [82,83,84].
The available clinical data also provides indirect support for the
possibility that resistance to interferon is not easily acquired over
the time scale of treatment. To date, the most likely causes for
therapeutic failure are non-compliance, insufficient drug levels or
dose reductions, drug toxicity, and interruptions in therapy–not
resistant, escape variants [85,86]. In fact, a study of the sequence
variability in the NS5A gene during treatment found no selection
of interferon resistant HCV strains [87]. Another study of the full
length polyprotein also found no significant difference in the
number of mutations between non-responders and relapsers [88].
Although accelerated mutational change with interferon treatment
was observed to occur in another study, such changes were notably
not related to treatment duration and therefore were not felt to
explain treatment non-response [89]. The available clinical
evidence, therefore, does not contradict the possibility that
resistance to interferon may be genetically difficult to acquire.
A third possible reason why different susceptibilities still exist is
that resistance to the immune system may come at some cost or
interfere with some other selective advantage. It is possible that the
earlier branching genotypes possess specialized functions that we
do not yet fully recognize, which compensate for their lack of
ability to interfere with the immune system. This possibility is
supported by reports of clinical differences in the course of disease
for different genotypes [90,91,92].
Fourth, it is possible that early branching genotypes maintain
higher susceptibilities because of host immune heterogeneity—i.e.
through diversifying selection. Numerous host factors have been
shown to effect clinical outcome [93]. One example is the
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tions have been shown to be a determinant of whether acute HCV
infection resolves or progresses to chronic infection [94]. A second
example of host heterogeneity is the observation that the binding
of interferon to its cellular receptor triggers a far more attenuated
transcriptional response in African-Americans compared to
Caucasians [95]. The SVR pattern of HCV may be a product
of all of these phenomena.
Complexities of HCV Biology and Evolution
We suggest that the human immune system has played a
significant role in shaping the evolution of HCV. However, it
seems highly unlikely that the evolution of HCV has been driven
by a single factor. In fact, other studies have emphasized
demographic and spatial history as the predominant forces in
HCV evolution [74]. This may explain why genotype 6 is endemic
to South East Asia while genotype 4 is endemic to central Africa
and the Middle East [18,65,96,97,98]. Such phylogeographic
explanations are not necessarily inconsistent with our results.
Epidemiological processes and immune selection may both have
played a role in HCV evolution. For instance, spread of HCV
between host populations with inherent immune differences could
have been a major evolutionary determinant.
We also acknowledge that this evolutionary analysis does not
explain why the treatment of acute HCV is genotype independent
[99,100]. We can only speculate that when acutely infected
patients are treated, their disease may not yet have established a
firm foothold, and that treatment overwhelms any viral inhibition
abilities. It may also be the case that chronic infection allows for
viral dissemination to more immune-protected regions of the host
[101].
In conclusion, the observed correlation between relative
genotype age and the probability of a sustained virologic response
supports our hypothesis that immune selection played a role in
HCV genotype level divergence. Such a correlation suggests the
intriguing forecast that prospective clinical trials for genotypes 5
and 6 will show intermediate response rates, between genotypes 4
and 2, to interferon-based regimens. This prediction is notably in
line with current retrospective data regarding the SVR for
genotype 5 [58]. It also highlights the need for more molecular
studies that explore the genotype-specificity of HCV-immune
interactions. Finally, this hypothesis provides a systematic
framework to explain, and by which to explore, the molecular
nature of non-responsiveness to clinical treatment for HCV.
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